Koelis

Koelis is a private, commercial-stage medical device company headquartered in Grenoble, France, focused on the oncology sector, specifically prostate cancer. The company's flagship product is the Koelis Trinity® system, an integrated mobile platform that fuses MRI and 3D ultrasound imaging to enable highly accurate, targeted prostate biopsies and focal therapies. Beyond its commercial technology, Koelis is actively conducting clinical research, such as the Violette trial, to validate focal microwave ablation as a treatment alternative, positioning itself as a comprehensive solution provider in the growing market for precision urology. The company generates revenue from the sale of its platform and is expanding its clinical evidence base to support broader adoption.

Koelis Trinity®: An integrated mobile platform combining MRI/3D ultrasound fusion, proprietary OBT Fusion® for real-time prostate tracking and 3D mapping, and automated motion compensation to guide precise prostate biopsies and focal therapies.

The market for prostate fusion biopsy systems is competitive, with major players like Philips (UroNav), BK Medical (acquired by GE), and Eigen. Koelis differentiates through its proprietary prostate-tracking (OBT Fusion®) and integrated mobile platform. The competitive landscape for focal therapy guidance is less crowded, offering a potential growth niche if clinical validation is successful.